A total of thirteen [10.8 %] adverse events (AEs) were
observed across four treatment groups. The patients treated
with NR-INF-02 exhibited least number of AEs during the
intervention period. The AEs in all the study groups were
mild and did not warrant the withdrawal of any study
medications (Table 6).